SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-030193
Filing Date
2021-12-01
Accepted
2021-12-01 16:08:55
Documents
20
Period of Report
2021-11-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50100
2 ex10-1.htm EX-10.1 185947
3 ex10-2.htm EX-10.2 171554
4 ex10-3.htm EX-10.3 4560
5 ex10-3_001.jpg GRAPHIC 181936
6 ex10-3_002.jpg GRAPHIC 293770
7 ex10-3_003.jpg GRAPHIC 293202
8 ex10-3_004.jpg GRAPHIC 230298
9 ex10-3_005.jpg GRAPHIC 82661
  Complete submission text file 0001493152-21-030193.txt   2157183

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE otlc-20211124.xsd EX-101.SCH 3028
11 XBRL LABEL FILE otlc-20211124_lab.xml EX-101.LAB 34240
12 XBRL PRESENTATION FILE otlc-20211124_pre.xml EX-101.PRE 22361
13 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3291
Mailing Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301
Business Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301 650-635-7000
Oncotelic Therapeutics, Inc. (Filer) CIK: 0000908259 (see all company filings)

IRS No.: 133679168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21990 | Film No.: 211463028
SIC: 2834 Pharmaceutical Preparations